Editorial
|
|
|
Grassroots healthcare professionals
|
|
|
Marketing Authorisations
|
|
|
Evidence of efficacy is missing
|
|
|
|
|
|
|
|
|
|
Unfortunately back on French market
|
|
|
|
|
|
|
|
Unjustified risks, no tangible benefit
|
|
|
|
|
|
EU marketing authorisation finally withdrawn
|
|
|
|
|
|
Unjustified marketing authorisation
|
|
|
Adverse Effects
|
|
|
Both conventional and atypical neuroleptics
|
|
|
|
|
|
Strict precautions needed
|
|
|
|
|
|
|
|
In rheumatoid arthritis patients
|
|
|
|
|
|
|
Do not inject promethazine
|
|
|
|
|
|
Paracetamol injection rarely justified
|
|
|
|
|
|
|
|
|
Beware cosmetic procedures
|
|
|
|
|
Reviews
|
|
|
Fluorouracil (+ folinic acid), oxaliplatin, irinotecan, combinations depending on the situation
|
|
Main chemotherapy protocols evaluated in metastatic colorectal cancer
|
|
|
|
|
|
|
Few data on cardiovascular prevention
|
|
|
|
|
|
|
When to halt resuscitation
|
|
|
|
|
|
|
Safer to avoid sales reps
|
|
|
|
|
|
A healthy dose of skepticism is needed
|
|
|
|
|
|
Weak evidence for 140/90 mmHg
|
|
|
|
|